The article discusses a study indicating that glucosamine, a common supplement often taken for joint pain, may have harmful effects on individuals with Alzheimer’s disease. Here are the key findings:
-
Increased Death Risk: People with Alzheimer’s who take glucosamine are 25% more likely to die within five years compared to those who do not take it.
-
Progression of Cognitive Decline: The study also found that individuals in the early stages of dementia (mild cognitive impairment) who took glucosamine were 25% more likely to progress to full Alzheimer’s.
-
Research Basis: The analysis involved anonymized medical records from a large cohort of patients with dementia and mild cognitive impairment.
-
Animal Studies: Experiments with mice that model Alzheimer’s symptoms showed that glucosamine worsened memory loss, while blocking the enzyme that produces such sugars improved symptoms.
-
Potential Mechanism: Alzheimer’s is associated with sugar buildup on brain cells and proteins, leading to dysfunction. Glucosamine, as an amino sugar, may exacerbate this issue.
-
Contrasting Studies: Prior studies linked glucosamine to lower dementia risk in cognitively healthy adults, but this study suggests it may have adverse effects in those with existing cognitive issues.
-
Need for Further Research: Questions remain about dosage, specific brands, and how long glucosamine should be taken. Future clinical trials are planned to explore these aspects further.
The article emphasizes caution regarding glucosamine use, particularly for individuals experiencing memory problems, and highlights the necessity of more controlled studies to establish a clear causal relationship.
